FDA De Novo Pathway: The Novel Device Guide (2026)

Every breakthrough device faces the same paradox: the FDA's fastest routes require a predicate, but a truly novel device has none. The De Novo pathway exists for exactly this situation — novel devices of low to moderate risk that cannot use 510(k) because no legally marketed predicate exists. It is how first-of-a-kind products get classified, and a granted De Novo becomes the predicate that every follower's 510(k) will cite. This guide covers when De Novo is the right route, the two ways in, the evidence bar, special controls, realistic timelines and costs, and the strategic value of being first.

This is planning intelligence, not legal or regulatory advice. It summarizes FDA requirements, guidance, and industry reporting as of September 2026. Submission requirements, user fees, and review timelines change — confirm every detail with qualified regulatory counsel before committing a calendar or a budget. Nothing here guarantees a grant.

When De Novo is the answer — and the terminology that matters

De Novo fits one situation precisely: a novel device, low to moderate risk, with no legally marketed predicate to claim substantial equivalence against. Force it into 510(k) and the submission dies on the predicate argument; push it to PMA and you pay for clinical evidence the risk level never required. The FDA grants De Novo requests — neither "clears" (510(k)) nor "approves" (PMA) — and the grant classifies the device into Class I or Class II, establishing special controls where the risk profile needs them.

The two ways in: direct De Novo vs post-NSE

The direct route is faster when the novelty is obvious — most sponsors with genuinely first-of-a-kind devices go direct. The post-NSE route is a hedge for borderline cases: if the 510(k) somehow clears, you saved the De Novo effort; if it comes back NSE, the record transfers and the De Novo builds on work already done.

The evidence bar: proving low-to-moderate risk

A De Novo does not need the full PMA clinical program, but it does need to prove the risk case from scratch — there is no predicate's history to lean on. The typical package: bench and animal testing, software and cybersecurity documentation, human-factors validation, and clinical data proportionate to the risk — often smaller and more focused than a PMA trial, but designed to answer the FDA's specific risk questions. The Q-Submission program is where the evidence plan gets aligned before money is spent: sponsors who agree the risk questions with the FDA upfront avoid the classic failure of answering questions nobody asked.

• Define the risk questions first — the De Novo lives or dies on whether the evidence answers them
• Use Q-Sub meetings to agree the evidence plan before generating data
• Build human-factors validation for any device with a user interface — use error is a top De Novo risk question
• Document software and cybersecurity to the FDA's risk-based expectations from the start
• Keep the quality system QMSR-aligned: the regulation is in effect since February 2026

Special controls: the classification's fine print

When a De Novo is granted as Class II, the FDA typically establishes special controls — device-specific requirements (performance standards, testing protocols, labeling elements) that future 510(k) submitters of the same device type must meet. This is the double-edged sword of being first: you write the rules, but you also do the work of defining them. Well-drafted special controls protect the pioneer by setting a bar followers must clear; vague ones invite low-quality follow-ons.

Timelines and costs: what to actually budget

The MDUFA V performance goal for a De Novo decision is 150 FDA days — again excluding industry response time, which is where most real-world delay lives. A well-prepared direct De Novo typically runs twelve to eighteen months from evidence plan to grant; post-NSE adds the 510(k) round first. De Novo user fees sit between 510(k) and PMA on the annual MDUFA schedule, with small-business reductions — this guide states no dollar figures because the schedule changes every fiscal year. The dominant cost driver is the evidence program, not the fee.

The strategic prize: becoming the predicate

The underappreciated value of a De Novo is competitive: the granted device becomes the predicate for every future 510(k) in its device type. The pioneer defines the classification, the special controls, and the testing expectations that followers must match. Companies that understand this treat the De Novo not as a regulatory burden but as a moat — the evidence package and special controls become the standard the whole category plays against.

For the structured pathway view — regulator, conformity route, and document logic — see the GHMAP regulatory pathways/united-states/class-ii page for the FDA route and the EU Class III regulatory pathway page for the EU's highest-risk route on ghmap.io.

Mistakes that kill De Novos

• Claiming novelty that is not there — if a predicate exists, the De Novo gets re-routed and months are lost
• Generating evidence before agreeing the risk questions with the FDA
• Underestimating human-factors validation for user-facing devices
• Accepting vague special controls that let weak followers through
• Treating the grant as the finish line instead of the start of a predicate franchise

De Novo is the pathway for devices that have no past — and its reward is defining the future. The sponsors who win it decide the risk questions with the FDA before spending, and write special controls that protect the category they just created.